Radiotherapy in the management of lung oligometastases
-
Published:2024-02
Issue:1
Volume:28
Page:36-48
-
ISSN:1278-3218
-
Container-title:Cancer/Radiothérapie
-
language:en
-
Short-container-title:Cancer/Radiothérapie
Author:
Bourbonne V.ORCID,
Lévy A.,
Khalifa J.,
Antoni D.,
Blais E.,
Darréon J.,
Le Péchoux C.,
Lerouge D.,
Giraud P.,
Marguerit A.,
Pourel N.,
Riet F.-G.,
Thureau S.
Reference188 articles.
1. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer;Borghaei;J Clin Oncol,2021
2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016
3. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study;Sun;Lancet,2021
4. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2020
5. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann Oncol,2015